Hospital
Clearfield Hospital
Clearfield Hospital was paid $614K by Medicaid between Jan 2018 and Aug 2021, across 138 billing codes. Its largest line is 99284, emergency room visit (serious) — 12% of everything it billed.
33Billing provider infoCLEARFIELD HOSPITAL
CLEARFIELD, PA 16830
CLEARFIELD, PA 16830
33aNPI1427022078assigned 02/13/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$614K
24GClaims27,485
24DCodes billed138
24AFirst – last monthJan 2018 – Aug 2021
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#108 of 154
Median peer was paid$2.82M
This provider vs. median0.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 111 | $714.66 | |
| 2019 | 28 | $14.57 | |
| 2020 | 586 | $6K | |
| 2021 | 26,760 | $607K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 885 | 829 | $74K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.5% | 873 | 822 | $59K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.5% | 492 | 452 | $52K |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 7.8% | 1,044 | 380 | $48K |
| G0299 | Direct skilled nursing services of a registered nurse (rn) in the home health or hospice setting, each 15 minutes | 7.7% | 424 | 114 | $48K |
| 87631 | 3.7% | 195 | 189 | $22K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.3% | 140 | 135 | $20K |
| 80050 | General health panel | 3.0% | 402 | 388 | $18K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.7% | 459 | 446 | $17K |
| G0378 | Hospital observation service, per hour | 2.1% | 13 | 12 | $13K |
| 80053 | Comprehensive metabolic panel | 1.9% | 1,477 | 1,239 | $12K |
| 80061 | Lipid panel | 1.5% | 733 | 718 | $9K |
126 more codes
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.5% | 333 | $9K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.3% | 66 | $8K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.3% | 161 | $8K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.3% | 103 | $8K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 1,842 | $8K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.2% | 432 | $7K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 109 | $7K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 300 | $6K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 158 | $6K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 136 | $6K |
| 0002A | <1% | 121 | $5K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 69 | $5K |
| 0001A | <1% | 127 | $5K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 665 | $4K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 139 | $4K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 550 | $4K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 169 | $4K |
| 83735 | <1% | 690 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 282 | $3K |
| 84439 | <1% | 411 | $3K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 139 | $3K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 511 | $3K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 457 | $3K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 91 | $3K |
| 87480 | <1% | 118 | $3K | |
| 87660 | <1% | 118 | $3K | |
| 73564 | <1% | 135 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 220 | $2K |
| 82607 | <1% | 224 | $2K | |
| 84702 | <1% | 159 | $2K | |
| 83721 | <1% | 213 | $2K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 195 | $2K |
| 83880 | <1% | 108 | $2K | |
| 82728 | <1% | 234 | $2K | |
| 84484 | <1% | 419 | $2K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 55 | $2K |
| 85027 | <1% | 378 | $2K | |
| 87081 | <1% | 316 | $2K | |
| 83970 | <1% | 55 | $2K | |
| 76830 | Ultrasound, transvaginal | <1% | 44 | $2K |
| 73610 | <1% | 112 | $2K | |
| 82784 | <1% | 79 | $2K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 35 | $2K |
| 71045 | Radiologic examination, chest; single view | <1% | 356 | $2K |
| 0012A | <1% | 40 | $2K | |
| 73030 | <1% | 118 | $2K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 156 | $2K |
| 86618 | <1% | 72 | $2K | |
| 87077 | <1% | 248 | $2K | |
| 0011A | <1% | 44 | $2K | |
| 81001 | <1% | 738 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 208 | $2K |
| 82043 | <1% | 221 | $1K | |
| 93971 | <1% | 25 | $1K | |
| 87040 | <1% | 89 | $1K | |
| 82570 | <1% | 246 | $1K | |
| 80076 | <1% | 166 | $1K | |
| 80320 | <1% | 107 | $1K | |
| 73630 | <1% | 137 | $1K | |
| 84153 | <1% | 49 | $1K | |
| 82746 | <1% | 127 | $1K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 15 | $1K |
| 83690 | <1% | 316 | $1K | |
| 72110 | <1% | 74 | $1K | |
| 87186 | <1% | 192 | $1K | |
| 73110 | <1% | 115 | $1K | |
| 86038 | <1% | 80 | $1K | |
| 85730 | <1% | 242 | $1K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 16 | $1K |
| 83605 | <1% | 191 | $887.33 | |
| 83540 | <1% | 117 | $858.09 | |
| 97161 | <1% | 26 | $825.64 | |
| 85610 | <1% | 377 | $808.92 | |
| 85379 | <1% | 96 | $707.51 | |
| 83615 | <1% | 132 | $695.49 | |
| 85652 | <1% | 272 | $689.31 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 42 | $688.65 |
| 73130 | <1% | 60 | $683.15 | |
| 84100 | <1% | 156 | $678.20 | |
| 84460 | <1% | 106 | $675.66 | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 34 | $668.80 |
| 84146 | <1% | 29 | $636.77 | |
| 71250 | <1% | 12 | $616.48 | |
| 84450 | <1% | 92 | $589.19 | |
| 82565 | <1% | 123 | $570.26 | |
| 84703 | <1% | 61 | $563.47 | |
| 86140 | <1% | 212 | $544.87 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 19 | $527.28 |
| 84550 | <1% | 105 | $477.42 | |
| 86334 | <1% | 32 | $466.47 | |
| 81003 | <1% | 143 | $410.61 | |
| 81025 | <1% | 111 | $391.60 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 197 | $362.74 |
| 73080 | <1% | 32 | $351.90 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 18 | $330.33 |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 14 | $313.11 |
| 82805 | <1% | 14 | $299.25 | |
| 74018 | <1% | 35 | $296.27 | |
| 87070 | <1% | 45 | $256.05 | |
| 86431 | <1% | 35 | $246.50 | |
| 82105 | <1% | 13 | $202.29 | |
| 83550 | <1% | 41 | $181.60 | |
| 84520 | <1% | 50 | $181.22 | |
| 86592 | <1% | 48 | $171.20 | |
| 82550 | <1% | 35 | $137.52 | |
| 87340 | <1% | 14 | $109.13 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 637 | $93.39 |
| 86850 | <1% | 14 | $83.70 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 194 | $82.02 |
| 82150 | <1% | 16 | $66.00 | |
| 82947 | <1% | 15 | $62.30 | |
| 36600 | <1% | 13 | $60.77 | |
| 86901 | <1% | 17 | $55.08 | |
| 86900 | <1% | 17 | $54.36 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 193 | $53.60 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 15 | $49.28 |
| 84156 | <1% | 13 | $36.08 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 31 | $35.70 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 19 | $34.21 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 34 | $17.12 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 0% | 125 | $0.00 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 37 | $0.00 |
| 96376 | 0% | 82 | $0.00 | |
| 87510 | 0% | 115 | $0.00 | |
| 3044F | 0% | 13 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 134 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBROWN, DANETTE (AUTHORIZED OFFICIAL)
| Provider | Location | Paid |
|---|---|---|
| Clearfield Hospital | Clearfield, PA | $543K |
| Clearfield Hospital | Clearfield, PA | $996.70 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.